Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
AI is shifting from cloud-rented models toward locally run, owned and open intelligence. ASUS/NVIDIA RTX Spark laptops pair with Nous Research's Hermes and ComfyUI, and Microsoft pushes hybrid local/cloud Windows. Cisco, NVIDIA and Marvell build open high-bandwidth AI infrastructure, and Hesai supplies real-world data for physical AI. In finance and commerce, Intuit, Zeta, Parloa/TELUS Digital and Snipp embed agentic AI into trusted financial and customer workflows, while OpenAI's math breakthroughs, its security disclosures and an executive's departure from its safety role keep safety and governance scrutiny high.
Palantir is drawing a cluster of bullish analyst calls (an upgrade to Buy, plus reiterations citing customer expansion, net dollar retention and a Goldman Sachs upgrade). In October it also announced AI partnerships across banking (Customers Bank), edge and sovereign infrastructure (Ondas/Regna AI, Armada) and others. Meanwhile, J.P. Morgan's Seth Seifman describes weak A&D sentiment, with a Leidos downgrade to Neutral and doubts about Boeing's 2027 cash flow, despite a near-record broader market. Speculative AI-adjacent names (D-Wave at 171x sales, Bloom, SMR) and event risk (Nov. 3 midterms, FY2027 budget talks) round out a market that pays up for AI adoption stories and is cautious on traditional government-linked sectors.
Finance leadership is turning over at companies such as Rivian, PJT Partners, Penguin Solutions and Fox Factory. Meanwhile CFOs are positioning their functions for agentic AI, as in the PwC/SAP collaboration, SAP's Autonomous Enterprise showcase and Morgan Foods' preparations. Regional banks such as Origin and BankUnited face deposit competition and Durbin Amendment pressure but report stable-to-improving margins (NIM 3.99%). Corporates are restructuring through productivity programs (NIKE's Pace model), divestitures and capital-structure moves, and several are scheduling Investor Days to reset expectations.
Oncology is seeing a run of regulatory wins and pipeline progress in Q4 2026: the FDA approved Tecentriq for adjuvant dMMR colon cancer, the EU CHMP backed a new Libtayo dosing regimen, ivonescimab has a BLA goal date of Nov 14, and intismeran data will be presented at ESMO. Capital is consolidating around oncology services and combinations, including McKesson and CD&R's acquisition of Option Care Health and the Summit/AstraZeneca/Daiichi Sankyo collaboration on ivonescimab plus Datroway in first-line TNBC. AstraZeneca's Puja Sapra frames AI as the long-term shift, with agentic, de novo biologics design and a 'lab of the future' that automates experiments. The AI claims are mostly opinion and forecast rather than demonstrated results. Several events in the set (Meta trial, rocket recovery, dinosaur research, Claude watermarks, Siemens hacking warning) are unrelated and were left out.
Small and mid-cap biotechs are rebuilding leadership and translational teams (Idorsia, MindWalk, Everest) while pushing pipelines toward IND filings and pivotal trials (Prelude, Ernexa, MapLight, Galectin). Revenue strength from royalties and obesity drugs (Leqembi, Eli Lilly, VivoSim's Lilly milestones) supports this. At the same time, AI-enabled biosecurity risk (jailbroken Kimi models giving bioweapon instructions) and new US AI governance (Jay Clayton named AI czar) add a regulatory overhang to AI-driven drug discovery.
Biotech AI is shifting from standalone models to integrated infrastructure: NVIDIA's BioNeMo, lab-in-the-loop collaborations with Lilly and Thermo Fisher, and a wave of foundation-model and agent launches (EDEN, Boltz Lab, OwkinZero, Kosmos, Researgent 2.0, Natera). Incumbents are reorganizing around this. Novo Nordisk closed its internal cell therapy unit and licensed its Parkinson's program to Cellular Intelligence, while MindWalk is building IP moats around biological data representation (HYFT, a new EP application). Markets have been receptive, with Novo's stock up about 25% in 30 days around its Q1 2026 earnings, though the evidence for AI-driven revenue is still thin and the claims are mostly company-promotional.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedFairfax India Holdings Corporation: Financial Results for the Year Ended December 31, 2025
“Fairfax India Holdings Corporation: Financial Results for the Year Ended December 31, 2025 NOTFORDISTRIBUTIONTOU.S.NEWSWIRESERVICESORDISSEMINATIONINTHEUNITEDSTATES (Note:All dollar amounts in this press release are expressed in U.S…”
Renault Group demonstrates its resilience, the robustness of its strategy, and moves forward with confidence
“Renault Group demonstrates its resilience, the robustness of its strategy, and moves forward with confidence RENAULT Press release February 19, 2026 Renault Group demonstrates its resilience, </b> the robustness of its strategy, </b> and moves forward with confidence</b> Renault Group achieved strong profitability and…”
Top Analyst Reports for Eli Lilly, Marriott & Fortinet
“Top Analyst Reports for Eli Lilly, Marriott & Fortinet Wednesday, February 11, 2026 The Zacks Research Daily presents the best research output of our analyst team…”
Deep Learning Market Size to Surpass $296B by 2031 as Autonomous Systems and Robotics are Set to Grow at 37.2% CAGR, Says a 2026 Mordor Intelligence Report
“Deep Learning Market Size to Surpass $296B by 2031 as Autonomous Systems and Robotics are Set to Grow at 37.2% CAGR, Says a 2026 Mordor Intelligence Report Hyderabad, India, Feb…”
Tower Semiconductor and Coherent Demonstrate 400Gbps/lane Data Transmission with a Silicon Modulator in a Production-Ready Sipho Process
“Tower Semiconductor and Coherent Demonstrate 400Gbps/lane Data Transmission with a Silicon Modulator in a Production-Ready Sipho Process Tower Semiconductor The demonstration uses a silicon MZM without use of exotic materials targeting next-generation 3.2T optical transceivers MIGDAL HAEMEK, Israel, March 23, 2026 - To…”
United Arab Emirates Gift Card Business Report 2026: $2.43 Bn Market Expands as Amazon and Majid Al Futtaim Anchor Retail Issuance While Banks and Super-Apps Broaden Distribution - Forecast to 2030
“United Arab Emirates Gift Card Business Report 2026: $2.43 Bn Market Expands as Amazon and Majid Al Futtaim Anchor Retail Issuance While Banks and Super-Apps Broaden Distribution - Forecast to 2030 Company Logo The UAE gift card market presents significant opportunities through digital innovation and integration with w…”
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts measure the same attribute (cash) for the same entity (Tesla Inc.) at the same point in time (2025-12-31). Although labeled with different fiscal period categories (FY 2025 vs Q4 2025), both periods end on the same date, making them equivalent time snapshots. The values differ drastically: $16.513 billion vs $44.06 USD. Since Q4 2025 is the final quarter of FY 2025, both should report identical cash balances at period-end. A 375 million-fold magnitude difference indicates a real contradiction, likely caused by a data quality issue (unit error, miscategorization, or source error in FACT B).
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Every fact is traceable to the document it came from — see how we source every claim.
Palantir fell to $186.03 after a 52-week high, yet analysts upgraded or backed it and new AI partnerships arrived. J.P. Morgan's defense analyst expects solid results from traditional defense firms that may not lift their shares. Every figure here traces to a named source, and we flag where the evidence is thin.
SEC filings show Micron's capital spending rose from $8.4 billion to $15.9 billion in a year, and its cash pile has grown sharply. Alliances, custom chips and optical links are forming around the same memory and data-movement bottleneck. The Wall Street bullishness comes from a source with a weak accuracy record.
Cancer medicine is changing on three fronts at once: next-generation drugs nearing decisions, AI-designed medicines, and a take-private of a care provider. Summit Therapeutics' audited filings show what one pivotal bet has cost: $1.08 billion lost in FY2025 with no revenue.
SEC-filed numbers show Micron nearly doubled its capital spending in fiscal 2025 and now holds about $25 billion in cash. Around it, chipmakers are locking in supply and merging. Several of the sources behind those deals have mixed accuracy records, and we show that below.
A cluster of cancer-drug milestones lands this autumn. One, a Phase 3 myeloma readout, has already reported a 51% cut in progression risk. Two more are dated: ESMO on Oct 24 and an FDA decision on Nov 14. We checked Merck's SEC-filed figures and weighed how reliable each source is.
Two dated events will test oncology's new tools within weeks: Merck and Moderna's personalized mRNA vaccine data at ESMO on Oct. 24, and the FDA decision on Summit's ivonescimab on Nov. 14. We checked Merck's SEC-filed numbers and flag where the sources are weak.
SEC-filed figures show Micron's capital spending roughly doubled in fiscal 2025 and its cash pile has since more than doubled in a year. Analysts back the AI-infrastructure names while flagging a 171x sales multiple at D-Wave and a split consumer. We also show how reliable each source is.
SEC filings show Micron's capital spending nearly doubled in fiscal 2025 and its cash pile has grown to about $25 billion. Analysts expect the AI chip shortage to last 12 to 18 months. We checked the numbers against filings and flagged where the analyst claims rest on weaker sources.
A survey reported by MIT Technology Review finds every respondent plans to use agentic AI within two years, yet AI reaches only part of company data. Money is moving to governance and data plumbing. We checked the figures, and the survey piece itself scores poorly on source reliability.
Several well-known companies announced new chief executives or CEO searches between July and early October 2026. Via News checked each against its source. The handoffs are mostly orderly, but one departure was abrupt, one company is still searching, and the sources' accuracy records vary widely.
Meta's new enterprise platform will be led by MongoDB's departing CEO, while small AI-native startups raise funding. Investors say back-office finance software is next, but one of them warns AI is bad at maths. We flag which sources are weaker and which parts of the story our evidence cannot yet support.
A survey says 100% of organizations plan to use AI agents within two years, yet only about 45% of company data is AI-accessible. We checked the claims against sources, and the survey's publisher scored poorly on reliability, so we flag that. Nvidia's SEC-verified costs show the build-out is real.
A personalised mRNA vaccine from Merck and Moderna stopped melanoma returning in a trial, and AstraZeneca is betting AI can speed up drug design. Via News checked what the record supports: some of the optimism rests on firm data, and some on sources that failed our own reliability tests.
Verified SEC figures show Nvidia's cost of revenue rose about 3.8 times in two fiscal years. A survey says every respondent plans to use AI agents, but company data and trust lag. That survey's source failed our check on all 11 claims we tested, so we flag it and lean on the data that held.
SEC-filed figures show Micron nearly doubled its capital spending in fiscal 2025 and now holds about 2.5 times the cash it had a year earlier. Analyst enthusiasm for power, data-center and quantum stocks rests on sources that held up only about half the time in our checks.
Companies from Manulife to Box customers are rolling out AI agents, and funding is flowing. But a trade-press study reports that in 'data laggard' firms, AI can reach 30% or less of company data. That source has a poor measured record, so we flag it as a claim, not a fact.
Every company surveyed by MIT Technology Review plans to use AI agents within two years, yet firms with weak data give those agents access to 30% or less of it. Only some of this is firmly established: that survey's source scores 0% on our reliability check, and the Nvidia figures are SEC-verified.
Adobe's weak guidance, Alphabet's negative free cash flow, and a wave of safety-driven departures from Anthropic, Google and OpenAI show investors and insiders both demanding proof, not promises — even as California moves first to regulate AI's reach into children's lives.
A single summit produced roughly $950 billion in AI infrastructure deals and locked Nvidia into South Korea's memory supply chain, while one research firm says Wall Street is still underpricing the memory chip boom behind it. Here's what's verified, what's just one analyst's call, and what's still speculative.
C3.ai's CEO sold $4.8 million in stock the same week the industry's biggest AI-agent-trust survey turned out unreliable on 11 checked claims, even as Manulife, Box and a wave of banking and healthcare startups commit real budgets. Via News separates the verified from the unverified.
Google now lets users strip visible watermarks from Gemini-made images, video and music — a move that cuts against the story of an industry rushing toward stronger AI-content labeling, and lands the same week OpenAI lost another senior executive.
Nvidia and South Korea's chipmakers signed roughly $950 billion in new AI agreements in July, including a deal to help secure Nvidia's HBM memory supply from SK Hynix, even as chip stocks logged a sharp correction and the Nasdaq 100 hit a 2.75-month low. Via News traces the deals, earnings and balance-sheet data behind the divergence.
A late-July selloff cut deep into AI-chip stocks — Micron fell nearly 40% from its peak — even as Nvidia expanded its SK hynix memory deal, GlobalFoundries signed a $300M federal photonics award, and Skyworks-Qorvo named a combined leadership team. The data show a maturing boom repricing risk, not a broken one.
Nearly all enterprises surveyed say they'll deploy AI agents within two years, but agents can typically reach under half of company data — and as little as 30% at 'data laggard' firms. Platform giants are selling governance; a new wave of startups is skipping the data problem by targeting narrow, auditable back-office tasks instead.
Brad Lightcap, OpenAI's special projects lead and the company's former chief operating officer, has announced his departure from the company.
Insurer Manulife, software firm Box and data platform Snowflake are each rolling out enterprise AI agent tools this year, spanning insurance, content management and data operations worldwide. A fintech startup, Casap, is building agents for dispute resolution, while enterprise leaders across regions report unclear governance for the technology.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.